Lower cognitive performance in healthy G2019S LRRK2 mutation carriers

Neurology

Volumn 79, Issue 10, 2012, Pages 1027-1032

  Thaler, Avner ^a,c   Mirelman, Anat ^a,d   Gurevich, Tanya ^a,c   Simon, Ely ^e,f   Orr Urtreger, Avi ^b,c   Marder, Karen ^g   Bressman, Susan ^h   Giladi, Nir ^a,c  

^a Movement Disorders Unit   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e NeuroTrax Corporation   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; EXECUTIVE FUNCTION; FEMALE; GENE MUTATION; GERIATRIC DEPRESSION SCALE; HETEROZYGOTE; HUMAN; HUMAN EXPERIMENT; LRRK2 GENE; MALE; MENTAL PERFORMANCE; MONTREAL COGNITIVE ASSESSMENT QUESTIONNAIRE; NORMAL HUMAN; OBSERVATIONAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; UNIFIED PARKINSONS DISEASE RATING SCALE PART III;

EID: 84866091335     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182684646     Document Type: Article

References (30)

1. Thaler A, Ash E, Gan-Or Z, Orr-Urtreger A, Giladi N. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. J Neural Transm 2009;116:1473-1482.
2. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006;354:424-425.
3. Orr-Urtreger A, Shifrin C, Rozovski U, et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology 2007;69:1595-1602.
4. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-590.
5. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672-680.
6. Siderowf A, Stern MB. Premotor Parkinson's disease: clinical features, detection, and prospects for treatment. Ann Neurol 2008;64(suppl 2):S139-S147.
7. Tomer R, Fisher T, Giladi N, Aharon-Peretz J. Dissociation between spontaneous and reactive flexibility in early Parkinson's disease. Neuropsychiatry Neuropsychol Behav Neurol 2002;15:106-112.
8. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.
9. Tomer R, Fisher T, Fray M, Gajewski BJ. Dissociation between spontaneous and reactive flexibility in Parkinson's disease. Int J Neurosci 2010;15:538-543.
10. Hanna-Pladdy B, Enslein A, Fray M, Gajewski BJ, Pahwa R, Lyons KE. Utility of the NeuroTrax computerized battery for cognitive screening in Parkinson's disease: comparison with the MMSE and the MoCA. Int J Neurosci 2010;120:538-543.
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
12. Fahn S, Elton R. Unified Parkinson's Disease Rating Scale. Florham Park, NJ: Macmillan Health Care Information; 1987.
13. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment J Am Geriatr Soc 2005;53:695-699.
14. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-1092.
15. Hausdorff JM, Doniger GM, Springer S, Yogev G, Simon ES, Giladi N. A common cognitive profile in elderly fallers and in patients with Parkinson's disease: the prominence of impaired executive function and attention. Exp Aging Res 2006;32:411-429.
16. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272-1277.
17. Hsieh YH, Chen KJ, Wang CC, Lai CL. Cognitive and motor components of response speed in the Stroop test in Parkinson's disease patients. Kaohsiung J Med Sci 2008;24:197-203.
18. Levy G, Jacobs DM, Tang MX, et al. Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord 2002;17:1221-1226.
19. Dujardin K, Defebvre L, Duhamel A, et al. Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients. J Neurol 2004;251:1383-1392.
20. Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 2005;18:149-154.
21. Johansen KK, White LR, Farrer MJ, Aasly JO. Subclinical signs in LRRK2 mutation carriers. Parkinsonism Relat Disord 2011;17:528-532.
22. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol 2010;67:798-801.
23. Stern MB, Lang A, Poewe W. Toward a redefinition of Parkinson's disease. Mov Disord 2012;27:54-60.
24. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 318:876-880, 1988.
25. Kehagia AA, Murray GK, Robbins TW. Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation. Curr Opin Neurobiol 2010;20:199-204.
26. Calabresi P, Picconi B, Parnetti L, Di Filippo M. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine- acetylcholine synaptic balance. Lancet Neurol 2006;5:974-983.
27. Caccappolo E, Alcalay RN, Mejia-Santana H, et al. Neuropsychological profile of parkin mutation carriers with and without Parkinson disease: The CORE-PD study. J Int Neuropsychol Soc 2011;17:91-100.
28. Rocca WA, Bower JH, Ahlskog JE, et al. Risk of cognitive impairment or dementia in relatives of patients with Parkinson disease. Arch Neurol 2007;64:1458-1464.
29. Marras C, Schule B, Munhoz RP, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011;77:325-333.
30. Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol 2011;69:193-197.